OLUMIANT

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, South Africa, Spain, UK.

Active ingredients

The drug OLUMIANT contains one active pharmaceutical ingredient (API):

1	Baricitinib UNII ISP4442I3Y - BARICITINIB
	Baricitinib is a selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2. In isolated enzyme assays, baricitinib inhibited the activities of JAK1, JAK2, Tyrosine Kinase 2 and JAK3 with IC50 values of 5.9, 5.7, 53 and >400 nM, respectively. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function.
	Read more about Baricitinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OLUMIANT Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AF02		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AF Janus-associated kinase (JAK) inhibitors
Discover more medicines within L04AF02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11437Y, 11442F, 11443G, 11447L
BR	Câmara de Regulação do Mercado de Medicamentos	507619020021501, 507619020021601, 507619020021701, 507619020021801
CA	Health Products and Food Branch	02480018
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	4543-MEE-0119, 4806-MEE-0919
EE	Ravimiamet	1739189, 1739190, 1739202, 1739213, 1739224, 1739235, 1739246, 1739257, 1739268, 1739279, 1739280, 1739291
ES	Centro de información online de medicamentos de la AEMPS	1161170002, 1161170010
FI	Lääkealan turvallisuus- ja kehittämiskeskus	407393, 579910
FR	Base de données publique des médicaments	61751780, 63788717
GB	Medicines & Healthcare Products Regulatory Agency	343458, 346212
HK	Department of Health Drug Office	65663, 65664
IE	Health Products Regulatory Authority	88875, 88876
IL	מִשְׂרַד הַבְּרִיאוּת	8307, 8308
IT	Agenzia del Farmaco	045260015, 045260027, 045260039, 045260041, 045260054, 045260066, 045260078, 045260080, 045260092, 045260104, 045260116, 045260128, 045260130, 045260142, 045260155, 045260167, 045260179, 045260181, 045260193
JP	医薬品医療機器総合機構	3999043F1020, 3999043F2026
LT	Valstybinė vaistų kontrolės tarnyba	1082320, 1082321, 1082322, 1082323, 1082324, 1082325, 1082326, 1082327, 1082328, 1082329, 1082330, 1082331, 1082332, 1082333, 1082334, 1082335
NL	Z-Index G-Standaard, PRK	140848, 140856
PL	Rejestru Produktów Leczniczych	100386120, 100386137
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63493001, W65630001
SG	Health Sciences Authority	15504P, 15505P
US	FDA, National Drug Code	0002-4182, 0002-4732
ZA	Health Products Regulatory Authority	52/3.1/0229, 52/3.1/0230